Androstadienone
AND · Δ4 · 16-androstadien-3-one · androsta-4 · 16-dien-3-one · 4 · 16-androstadien-3-one
Last updated
At a glance
Overview
Why Androstadienone Earned Its Place in the Looksmaxxing Stack#
Androstadienone is the most-studied human chemosignal in the literature — a 16-androstene steroid found in male sweat, saliva, and skin lipids that produces measurable CNS effects in recipients without any androgenic or anabolic activity in the wearer. The looksmaxxing and DIY-fragrance communities reach for it because the documented effects are exactly the ones that matter in social and dating contexts: biased female attention toward emotional cues, modest elevation in attractiveness ratings of the wearer, sustained cortisol modulation, and hypothalamic activation in heterosexual female (and homosexual male) recipients.
Crucially, the strongest effects in the literature appear at concentrations below the conscious odor threshold — this is a fixative-range chemosignal, not a top-note fragrance. The practical implication is that less is more: trace dosing into a masking base (sandalwood, vetiver, clove, ambroxan) outperforms heavy-handed application, which tips into the urinous-musky note that OR7D4-sensitive perceivers find unpleasant.
"Behavioral effects were evident even at concentrations below the conscious odor detection threshold for most participants." — Lundström et al., Hormones and Behavior (2003)
The sections below cover documented androstadienone concentrations and per-application dose ranges, the standard androstenone / androstenol stack ratios used in DIY blends, recipient response data (including the sex-, orientation-, and genotype-dependence that determines whether the signal lands), and the common formulation mistakes that turn a working chemosignal into an unwearable fragrance.
How Androstadienone works
Androstadienone is a 16-androstene class steroid produced endogenously in male apocrine sweat, saliva, and semen. Despite the steroidal backbone, it has no documented androgen-receptor activity and is not anabolic, androgenic, or aromatizable. Its entire pharmacological profile sits in the chemosensory domain — it is detected through the main olfactory epithelium and produces sex- and orientation-specific CNS effects, often at concentrations well below the conscious odor threshold. Five distinct mechanisms are worth understanding before designing a fragrance protocol around it.
Olfactory Detection via the Main Olfactory Epithelium#
The vomeronasal organ is non-functional in adult humans, so androstadienone is not a "VNO pheromone" in the rodent sense. Detection occurs through conventional olfactory receptors in the main olfactory epithelium — most prominently OR7D4, a G-protein-coupled receptor whose common polymorphisms (RT vs. WM variants) explain a large fraction of the population-level variance in perceived intensity and valence. Carriers of the RT/RT genotype perceive androstadienone as sharp and urinous; WM carriers often perceive it as faint, sweet, or nothing at all. This is why recipient response is bimodal in every published cohort — the molecule is being detected, but the conscious percept varies wildly.
"Androstadienone is a 16-androstene derivative produced endogenously in male sweat and exerts sex- and orientation-specific CNS effects via the main olfactory epithelium." — Ye, Yang & Zhou, Handbook of Clinical Neurology, 2021
The practical consequence: behavioral effects appear even when the recipient cannot consciously identify any odor, and over-dosing into the perceptible range tends to hurt the signal rather than amplify it.
Hypothalamic Activation — Sex- and Orientation-Specific#
fMRI work consistently shows that androstadienone activates the anterior hypothalamus and preoptic area in heterosexual women and homosexual men, but not in heterosexual men. This is the same circuit that processes sexually relevant chemosensory information across mammals, and it is the anatomical substrate for the downstream cortisol, attentional, and mood effects below. The asymmetry — recipients whose hypothalamus responds versus those whose doesn't — is why the fragrance use-case is asymmetric. Androstadienone signals to female recipients; it does little to nothing as a wearer-facing nootropic.
HPA-Axis Modulation and Sustained Cortisol Elevation#
The most cleanly documented endocrine effect is HPA-axis activation in female recipients. A single upper-lip application in lab conditions elevates salivary cortisol for over an hour — direct evidence that a single sweat constituent can modulate the stress / arousal axis without conscious awareness.
"Inhalation of androstadienone by women led to a sustained elevation of salivary cortisol levels for over one hour." — Wyart, Webster, Chen, Wilson, McClary, Khan & Sobel, Journal of Neuroscience, 2007
In the looksmaxxing context this is not a side effect to mitigate — it is the mechanism. Mild cortisol elevation in a recipient maps onto subjective arousal, attentional engagement, and physiological alertness. This is also why the effect window matches a real social interaction (dinner, conversation, a date) rather than a brief encounter.
Frontolimbic Attunement to Emotional Information#
Beyond raw arousal, androstadienone biases attention toward emotional content specifically. Hummer & McClintock demonstrated faster dot-probe latencies to emotional faces and Stroop interference with emotional words — but no effect on neutral cognitive Stroop performance. Later fMRI work tied this to altered connectivity between the amygdala and orbitofrontal cortex during emotional-face processing.
"Androstadienone exposure selectively enhanced women's attention to emotional faces in dot-probe tasks, without altering basic cognitive performance." — Hummer & McClintock, Hormones and Behavior, 2009
Practically: a recipient under androstadienone exposure isn't being "drugged" into compliance — she is being tuned to pay closer attention to facial affect, eye contact, and emotional cues from whoever she is interacting with. The wearer's grooming, expression, and social skill still do the work; the chemosignal raises the gain on the channel.
Mood and Perception Biasing — and Why the Effect Is Sub-Threshold#
The behavioral payoff sits in mood and attractiveness perception. Female recipients exposed to androstadienone show elevated positive mood and rate ambiguous male faces as more attractive; male recipients show neutral-to-mildly-negative mood shifts in the same paradigm.
"Exposure to androstadienone induced positive mood in female recipients, but neutral or mildly negative effects in male recipients." — Jacob & McClintock, Hormones and Behavior, 2000
"Women exposed to androstadienone rated male faces as significantly more attractive compared to the control condition during a speed-dating event." — Saxton, Lyndon, Little & Roberts, Hormones and Behavior, 2008
Crucially, these effects are most reliable when androstadienone is delivered below the conscious detection threshold — either masked by a conventional fragrance base or dosed in the trace range.
"Behavioral effects were evident even at concentrations below the conscious odor detection threshold for most participants." — Lundström, Gonçalves, Esteves & Olsson, Hormones and Behavior, 2003
This is the single most important translation from lab to fragrance bench: the goal of a working blend is sub-threshold exposure paired with a masking base (sandalwood, vetiver, clove, ambroxan), not a perceptible musky note. Over-concentrate the compound and the OR7D4-sensitive fraction of perceivers consciously identifies it as urinous — which inverts the effect entirely.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 0.1–0.5 mcg | As needed | Documented entry-level range |
| Mid | 0.5–2 mcg | As needed | Most commonly studied range |
| High | 2–10 mcg | As needed | Applied per occasion to pulse points (neck, sternum, behind ears) 20–30 min before social contact. Lab protocols use a 250 μM solution (~67.6 μg/mL) applied to the upper lip; community fragrance practice uses 1–10 μg per spray. No tolerance or desensitization on relevant timescales — dosing cadence is event-driven, not cyclical. |
Cycle length & outcomes
Cycle Structure#
Androstadienone doesn't cycle in any meaningful sense. It is a topical chemosignal applied per occasion, not a systemic agent — there is no receptor downregulation, no HPTA involvement, and no documented tolerance on timescales relevant to social use. The "protocol" question is really two questions: what concentration to blend at, and when to apply for a given social context.
Dose Ladder by Use Case#
| Use Case | Application Cadence | Per-Spray Dose | Blend Concentration |
|---|---|---|---|
| Beginner / scent-tolerance testing | Single application, low-stakes setting | 0.1–0.5 μg | 1–5 μg/mL (0.0001–0.0005% w/v) |
| Standard social / date-night | Per occasion, 20–30 min pre-contact | 0.5–2 μg | 5–20 μg/mL (0.0005–0.002% w/v) |
| Dense-social-context (bars, parties, speed-dating analogs) | Per occasion, 2–3 pulse points | 2–10 μg | 20–100 μg/mL (0.002–0.01% w/v) |
| Laboratory-equivalent (research replication) | Single upper-lip application | ~10–30 μg total | 250 μM (~67.6 μg/mL) in propylene glycol |
Community DIY practice clusters at the lower end (≤5 μg per spray, ≤0.005% w/v in the finished blend) specifically to stay sub-threshold for OR7D4-sensitive perceivers who experience the raw compound as a sharp urinous-musky note.
Onset and Duration#
Effects in the recipient develop within 5–6 minutes of olfactory contact and persist throughout the documented observation windows (60–120 minutes).
"Inhalation of androstadienone by women led to a sustained elevation of salivary cortisol levels for over one hour." — Wyart et al., J Neurosci (2007)
For practical purposes, a single application 20–30 minutes before contact covers a 1–2 hour social window. Reapplication mid-evening is reasonable for longer engagements (dinner → drinks → after-hours), though there is no evidence that stacked applications produce stronger effects — the response curve plateaus rather than scaling linearly with dose.
Loading and Tapering#
Neither is applicable. There is no biological mechanism for an androstadienone "loading phase" — the compound acts on the recipient's olfactory and limbic systems on first exposure, not the wearer's endocrine system. Likewise, there is nothing to taper from: no suppression, no rebound, no PCT analog.
The one cadence consideration is same-recipient habituation in long-term partner contexts. The literature has not directly characterized this, but the broader olfactory adaptation literature suggests a partner who is exposed daily to the same chemosignal will register diminished novelty over weeks. The signal is most useful in novel-encounter contexts (first dates, parties, dense social environments) rather than as a daily fragrance with an established partner.
Sub-Threshold Targeting#
The single most important protocol variable is staying below the conscious-detection threshold for the recipient. Effects are documented at concentrations the recipient cannot consciously smell.
"Behavioral effects were evident even at concentrations below the conscious odor detection threshold for most participants." — Lundström et al., Horm Behav (2003)
This is why a 1–5 μg/mL blend in a sandalwood, vetiver, or ambroxan base outperforms a higher-concentration "pheromone cologne" — the masking base keeps the androstadienone signal sub-threshold while still delivering it to the recipient's olfactory epithelium. Over-dosing into the perceptible range is the most common DIY failure mode and tends to produce worse social outcomes than no application at all.
Recipient Context Matters More Than Dose#
The audience response data is sharply sex- and context-dependent.
"Exposure to androstadienone induced positive mood in female recipients, but neutral or mildly negative effects in male recipients." — Jacob & McClintock, Horm Behav (2000)
"Women exposed to androstadienone rated male faces as significantly more attractive compared to the control condition during a speed-dating event." — Saxton et al., Horm Behav (2008)
Practical implication: the protocol is built around target audience, not dose escalation. A blend applied to a male-heavy environment (a competitive workplace, a bachelor party, a men's-room encounter) can shift dominance perception in directions the wearer didn't intend. Female-recipient and homosexual-male-recipient contexts are where the documented mood and attention effects land cleanly.
Bloodwork and Monitoring#
None required. There is no systemic exposure to monitor, no hepatic or renal load, no lipid or hormonal impact. Wyart 2007 documented elevated cortisol in the female recipient, not the wearer — the wearer's endocrine system is uninvolved. Feedback is behavioral, which makes self-assessment unreliable, so most experienced users calibrate blend concentration with a trusted second opinion (a close female friend or partner who can confirm the finished fragrance reads as a pleasant base musk rather than a urinous note) before deploying in live social contexts.
Stacking Within a Single Blend#
Androstadienone is rarely run alone in community practice. The standard looksmaxxing pheromone stack:
| Component | Role | Ratio (relative to AND) |
|---|---|---|
| Androstadienone | Mood / attention / attractiveness biasing in female recipients | 1 |
| Androstenone | Dominance / intimidation signal | 1–2 |
| Androstenol (3α and/or 3β) | Warm, approachable, "friendly" signal | 2–4 |
| Masking base (sandalwood, vetiver, ambroxan, clove) | Sub-threshold delivery vehicle | bulk carrier |
The ratio skews toward androstenol-heavy in approachable / dating contexts and androstenone-heavier in dominance-coded contexts (negotiation, competitive social environments). Citrus and aldehyde top-notes clash badly with the 16-androstene base and should be avoided in the same blend.
Documented protocols treat androstadienone as a per-occasion social tool with a flat dose-response curve above the trace-blend threshold — not a compound to cycle, load, taper, or monitor.
Risks & mistakes
Common (most users)#
- Perceptible urinous-musky note at the application site. The single most frequent complaint from wearers and proximate recipients. Driven by over-concentration in the carrier — the literature consistently shows effects are cleanest below the conscious-odor threshold (Lundström et al., 2003). Mitigation: keep finished-fragrance concentration at 1–5 μg/mL (≤0.0005% w/v) and pair with a sandalwood, vetiver, clove, or ambroxan base that absorbs the musky note.
- Mild skin dryness at the application site. A function of the ethanol or DPG carrier, not the molecule itself. Mitigation: switch to a DPG-heavier carrier, or apply to clothing fibres (collar, scarf) rather than directly to skin.
- Inconsistent results across social contexts. Effects are context-dependent — documented in mixed-sex or female-recipient settings, weak or absent in solo or male-dominant settings (Hummer & McClintock, 2009; Jacob & McClintock, 2000). Not a side effect in the medical sense — but the most common community complaint, and worth calibrating expectations around.
Uncommon (dose-dependent or individual)#
-
Cortisol elevation in female recipients. Documented by Wyart 2007 as a sustained rise lasting ≥60 minutes after a single upper-lip application:
"Inhalation of androstadienone by women led to a sustained elevation of salivary cortisol levels for over one hour." — Wyart et al., 2007, J Neurosci
This is part of the arousal/attention signature and is not framed as adverse in the literature, but in already-stressed recipients it can read as agitation rather than engagement. Mitigation: lower the per-application dose and lean on the androstenol fraction of the stack for warmth.
-
Negative mood shift in male recipients. Documented across the chemosignal literature — male recipients show neutral-to-mildly-negative mood responses where female recipients show positive ones:
"Exposure to androstadienone induced positive mood in female recipients, but neutral or mildly negative effects in male recipients." — Jacob & McClintock, 2000, Horm Behav
Relevant for wearers in male-dense environments (competitive workplace, men's locker room, bar full of guys). Mitigation: reserve androstadienone-heavy blends for mixed-sex or female-recipient contexts; switch to androstenol-dominant blends for male-recipient social settings.
-
Self-exposure mood/attention shift in the wearer. Some male users applying to their own upper lip report the same neutral-to-negative mood drift documented in the lab. Mitigation: apply to neck/sternum/clothing rather than philtrum if the wearer is olfactorily sensitive to the molecule.
-
Anosmic recipients show no response. OR7D4 polymorphisms make a meaningful fraction of the population functionally insensitive to androstadienone. Not harmful — just a null result. No mitigation other than recognising the genotype variance is real and effect sizes in any given encounter are probabilistic.
Rare but serious#
There are no documented serious adverse events from topical or olfactory androstadienone exposure at the concentrations used in published studies or in fragrance-community practice. The compound is endogenously produced in male sweat at concentrations far exceeding anything applied as a finished fragrance, and there is no published toxicology signal from exogenous exposure. No hepatotoxicity, no nephrotoxicity, no endocrine disruption, no neurotoxicity has been documented in the chemosignal literature spanning ~25 years of human exposure studies (Ye et al., 2021, Handbook of Clinical Neurology).
Hard contraindications#
- Anosmia to androstadienone in the target audience. If the intended recipient carries the OR7D4 RT/RT or WM/WM variant that abolishes detection, the chemosignal does nothing — wasted carrier and a strong musk note for everyone else in proximity. Not dangerous, but a hard "do not deploy here."
- Male-dominant social context where the wearer wants to be liked by other men. Androstadienone biases male perceivers toward seeing other males as more dominant and increases gaze avoidance in socially anxious male observers (Ye et al., 2021). Wrong tool for a job interview with male decision-makers, a men's group dinner, or any setting where coming across as non-threatening to men matters.
- Citrus / aldehyde-heavy fragrance pairings. Bergamot, lemon, neroli, Hedione, and most aldehydic top notes clash chemically and perceptually with the C19 musk base — the result is the perceptible urinous note coming through rather than blending into the fixative layer. The base must be sandalwood, vetiver, clove, oud, ambroxan, or a similar warm/musky/resinous register.
Gender and hormonal considerations#
Androstadienone is non-androgenic and non-anabolic — it does not bind AR, does not aromatize to estradiol, and is not a substrate for 5α-reductase in the active-androgen direction (it reduces to androstenone, itself a non-androgenic pheromone). This makes it fully compatible with AAS cycles, TRT, finasteride / dutasteride, topical RU58841 or pyrilutamide, and SARM protocols. No HPTA suppression, no impact on lipids, no impact on hematocrit, no impact on prostate markers. PCT is not required and not relevant — the compound has no endocrine axis to recover from. Female users wearing androstadienone-containing blends face the same considerations as male users; the gender split in the literature is about recipient response, not wearer safety. No documented pregnancy contraindication for topical exposure at fragrance-trace concentrations.
FAQ — Androstadienone
Research & citations
6 studies cited on this page.
Conclusion
Androstadienone occupies a unique slot in the looksmaxxing toolkit — a research-backed chemosignal with well-documented effects on mood, attention, and attractiveness ratings, delivered in a sub-threshold trace dose.
Key takeaways:
- Protocol dosing: 0.1–2 µg per application as a finished fragrance (trace-fixative range), rarely exceeding 10 µg per pulse
- Route: topical to skin at pulse points or upper lip, diluted in ethanol or DPG and blended into a masking fragrance (sandalwood, vetiver, clove)
- Timing: applied 20–30 min before social contact; behavioral effects persist ≥1 hour (Wyart et al., 2007)
- Headline benefit: enhances female mood, attention, and perception of male attractiveness in mixed social environments (Jacob & McClintock, 2000; Saxton et al., 2008)
- Best stacked with androstenone and androstenol (1:1:2 to 1:2:4) in a non-citrus fragrance base
- Real-world effect size: subtle but measurable; most effective when sub-threshold and paired with a compatible context or protocol
With a solid literature base and clear, manageable protocol design, androstadienone is one of the few "pheromone" compounds whose effects persist under real-world scrutiny. For those optimizing social presence and perceived approachability, the research and community practice both support its niche.